Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization

Posted Jun 05 2013 8:00pm

Description of Invention:
The technology includes patent rights and related materials for live attenuated viruses that can be used as a prophylactic vaccine against respiratory syncytial virus. The viruses are generated using codon-pair deoptimization techniques, resulting in attenuation based on hundreds or thousands of nucleotide substitutions with no differences at the amino acid level. Various permutations are based on deoptimization of the RSV polymerase ORF, the F and G glycoprotein ORFs, the NS1, NS2, N, P, M, and SH ORFs, or all of these in combination. Experimental growth data for representative viruses in mice and in African Green Monkeys demonstrated in vivo growth attenuation.

Applications:
  • Prophylactic vaccine
  • Childhood vaccine


Advantages:
  • Live attenuated
  • Codon deoptimized


Development Status:
  • Pre-clinical
  • In vivo data available (animal)


Inventors:
Peter L Collins (NIAID)
Cyril J Le Nouen (NIAID)
Linda G Brock (NIAID)
Ursula Buchholz (NIAID)
Joshua M DiNapoli (NIAID)
Steffen Mueller (State University of New York (SUNY) at Stony Brook)
Eckard Wimmer (State University of New York (SUNY) at Stony Brook)


Patent Status:
HHS, Reference No. E-080-2013/0
US, Application No. 61/762,768 filed 08 Feb 2013
US, Application No. 61/794,155 filed 15 Mar 2013


Relevant Publication:
  1. Collins PL, Melero JA. [ PMID 21963675 ]
  2. Coleman JR, et al. [ PMID 18583614 ]



For Licensing Information Please Contact:
Michael Shmilovich Esq.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019
Fax: 301-402-0220


Ref No: 2570

Updated: 06/2013

Post a comment
Write a comment:

Related Searches